Comprison of Cost-effectiveness Ratio Between Recombinant Human Growth Hormone and Human Serum Albumin in Treating Liver Cirrhosis With Hypoproteinemia / 中国药房
China Pharmacy
;
(12)2001.
Artigo
em Chinês
| WPRIM
| ID: wpr-518079
ABSTRACT
AIM:
To compare the therapeutic effects, adverse reactions and the costs between recombinant human growth hormone(rhGH) and human serum albumin(HSA) in treatment of liver cirrhosis patients with hypoproteinemiaMETHODS:
Using pharmacoeconomic cost-effectiveness analysis , rhGH was compared with HSA in treatment of 66 liver cirrhosis patients with hypoproteinemia(divided into two groups).RESULTS:
After 4 weeks treatment, the effective rates of rhGH and HSA we- re 69.70% and 84.85%, the cost-effectiveness ratios were 27.36, 38.89, respectively. After 8 weeks treatment, the effective rates of rhGH and HSA were 78.79% and 54. 57% ,the cost-effectiveness ratios were 2420, 60.47, respectively. CONCLUSI- ON rhGH can effectively treat liver cirrhosis with hypoproteinemia and can obviously increase serum albumin level. From a Long-term point of view, its cost effectiveness ratio is superior to that of HSA.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Avaliação Econômica em Saúde
Idioma:
Chinês
Revista:
China Pharmacy
Ano de publicação:
2001
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS